IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery ( JVS1). The study demonstrated that the DETOUR…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
